FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1938529209> ?p ?o ?g. }

• W1938529209 endingPage "1856" @default.
• W1938529209 startingPage "1848" @default.
• W1938529209 abstract "PURPOSE A randomized trial was performed in premenopausal postoperative women with ipsilateral axillary node-positive (N+) breast carcinoma and known estrogen receptor (ER) status to assess the efficacy of an Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH)-based induction regimen and 5 or more years of tamoxifen (Tam). PATIENTS AND METHODS Patients received 12 28-day cycles of cyclophosphamide 100 mg/m2 orally days 1 to 14, methotrexate 40 mg/m2 intravenously (IV) days 1 and 8, fluorouracil 600 mg/m2 IV days 1 and 8, prednisone 40 mg/m2 orally days 1 to 14, and Tam 10 mg orally twice daily (CMFPT), or the same regimen plus halotestin 10 mg orally twice daily (CMFPTH) alternating monthly with 22-day cycles of vinblastine 4.5 mg/m2 IV day 1, Adriamycin 45 mg/m2 IV day 1, thiotepa 12 mg/m2 IV day 1, halotestin, and Tam (ALTER). Prednisone in the ALTER regimen was stopped after the second CMFPTH cycle. After 12 cycles, patients were again randomized to stop or continue Tam. After 5 years, patients on Tam were again randomized to continue or stop Tam; the results from this randomization are still coded. Among 533 analyzed induction cases, 263 received CMFPT and 270 ALTER. Among 396 analyzed maintenance cases, 201 continued Tam and 195 were observed. Pretreatment characteristics were balanced among treatments. The median follow-up times are 5.1 years for induction and 4.1 years for maintenance. RESULTS The time to relapse (TTR) was superior for the ALTER regimen (P = .04) and for the maintenance Tam (P = .05). Overall survival comparisons between the regimens are not statistically different. A longer TTR was associated with decreasing nodal involvement, ER+ status, and increasing age. The favorable effects of decreasing nodal involvement and ER+ status carried over to survival; a progesterone receptor-positive (PgR+) status and decreasing tumor size were also associated with longer survival. Development of amenorrhea was associated with improved TTR and survival. Toxicity was similar for the two induction regimens and for the two maintenance regimens. Overall relapse patterns were similar among the induction regimens, but continuing Tam led to fewer locoregional relapses. CONCLUSION The results suggest significant overall TTR therapeutic benefits of an Adriamycin-containing alternating induction regimen and of continuing maintenance Tam therapy for at least 5 years." @default.
• W1938529209 created "2016-06-24" @default.
• W1938529209 creator A5023530978 @default.
• W1938529209 creator A5035654267 @default.
• W1938529209 creator A5046746238 @default.
• W1938529209 creator A5068911739 @default.
• W1938529209 creator A5074320591 @default.
• W1938529209 creator A5077630952 @default.
• W1938529209 creator A5078129443 @default.
• W1938529209 creator A5083684613 @default.
• W1938529209 date "1992-12-01" @default.
• W1938529209 modified "2023-09-26" @default.
• W1938529209 title "Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial." @default.
• W1938529209 cites W118403476 @default.
• W1938529209 cites W1566473841 @default.
• W1938529209 cites W1580788756 @default.
• W1938529209 cites W1929485622 @default.
• W1938529209 cites W1966216790 @default.
• W1938529209 cites W1967865481 @default.
• W1938529209 cites W1968380749 @default.
• W1938529209 cites W1969965083 @default.
• W1938529209 cites W1979300931 @default.
• W1938529209 cites W1983647986 @default.
• W1938529209 cites W1991250143 @default.
• W1938529209 cites W1993394125 @default.
• W1938529209 cites W1999306826 @default.
• W1938529209 cites W2001783515 @default.
• W1938529209 cites W2002041504 @default.
• W1938529209 cites W2032566866 @default.
• W1938529209 cites W2039642936 @default.
• W1938529209 cites W2040082843 @default.
• W1938529209 cites W2044202393 @default.
• W1938529209 cites W2045179615 @default.
• W1938529209 cites W2051536649 @default.
• W1938529209 cites W2061983141 @default.
• W1938529209 cites W2069074375 @default.
• W1938529209 cites W2076668534 @default.
• W1938529209 cites W2077773619 @default.
• W1938529209 cites W2079511840 @default.
• W1938529209 cites W2083564740 @default.
• W1938529209 cites W2114081348 @default.
• W1938529209 cites W2120079339 @default.
• W1938529209 cites W2133028092 @default.
• W1938529209 cites W2187668060 @default.
• W1938529209 cites W2271771009 @default.
• W1938529209 cites W2300271947 @default.
• W1938529209 cites W2335332412 @default.
• W1938529209 cites W2339705539 @default.
• W1938529209 cites W2413853954 @default.
• W1938529209 cites W2414533823 @default.
• W1938529209 cites W2797177778 @default.
• W1938529209 cites W3157593421 @default.
• W1938529209 cites W90336627 @default.
• W1938529209 cites W181023844 @default.
• W1938529209 doi "https://doi.org/10.1200/jco.1992.10.12.1848" @default.
• W1938529209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1453199" @default.
• W1938529209 hasPublicationYear "1992" @default.
• W1938529209 type Work @default.
• W1938529209 sameAs 1938529209 @default.
• W1938529209 citedByCount "67" @default.
• W1938529209 countsByYear W19385292092012 @default.
• W1938529209 countsByYear W19385292092013 @default.
• W1938529209 countsByYear W19385292092014 @default.
• W1938529209 countsByYear W19385292092015 @default.
• W1938529209 countsByYear W19385292092017 @default.
• W1938529209 countsByYear W19385292092019 @default.
• W1938529209 countsByYear W19385292092022 @default.
• W1938529209 crossrefType "journal-article" @default.
• W1938529209 hasAuthorship W1938529209A5023530978 @default.
• W1938529209 hasAuthorship W1938529209A5035654267 @default.
• W1938529209 hasAuthorship W1938529209A5046746238 @default.
• W1938529209 hasAuthorship W1938529209A5068911739 @default.
• W1938529209 hasAuthorship W1938529209A5074320591 @default.
• W1938529209 hasAuthorship W1938529209A5077630952 @default.
• W1938529209 hasAuthorship W1938529209A5078129443 @default.
• W1938529209 hasAuthorship W1938529209A5083684613 @default.
• W1938529209 hasConcept C121608353 @default.
• W1938529209 hasConcept C126322002 @default.
• W1938529209 hasConcept C126894567 @default.
• W1938529209 hasConcept C141071460 @default.
• W1938529209 hasConcept C143998085 @default.
• W1938529209 hasConcept C168563851 @default.
• W1938529209 hasConcept C204243189 @default.
• W1938529209 hasConcept C2776694085 @default.
• W1938529209 hasConcept C2776755627 @default.
• W1938529209 hasConcept C2777176818 @default.
• W1938529209 hasConcept C2779968505 @default.
• W1938529209 hasConcept C2781413609 @default.
• W1938529209 hasConcept C530470458 @default.
• W1938529209 hasConcept C71924100 @default.
• W1938529209 hasConcept C90924648 @default.
• W1938529209 hasConceptScore W1938529209C121608353 @default.
• W1938529209 hasConceptScore W1938529209C126322002 @default.
• W1938529209 hasConceptScore W1938529209C126894567 @default.
• W1938529209 hasConceptScore W1938529209C141071460 @default.
• W1938529209 hasConceptScore W1938529209C143998085 @default.
• W1938529209 hasConceptScore W1938529209C168563851 @default.
• W1938529209 hasConceptScore W1938529209C204243189 @default.

• next